Low-dose aspirin and cancer mortality: A meta-analysis of randomized trials

American Journal of Medicine

Volumn 125, Issue 6, 2012, Pages 560-567

  Mills, Edward J ^a   Wu, Ping ^a   Alberton, Mark ^a   Kanters, Steve ^b   Lanas, Angel ^c   Lester, Richard ^d  

^a UNIVERSITY OF OTTAWA   (Canada)

^b SIMON FRASER UNIVERSITY   (Canada)

^c HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Acetylsalicylic acid; Aspirin; Cancer; Meta analysis; Neoplasms; Randomized trials

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO;

ARTICLE; BIOLOGICAL MONITORING; CANCER MORTALITY; CONFIDENCE INTERVAL; ELECTRONIC MEDICAL RECORD; FATALITY; FOLLOW UP; HUMAN; LOW DRUG DOSE; META ANALYSIS; MODEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SAMPLE SIZE; TREATMENT DURATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DRUG ADMINISTRATION SCHEDULE; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK;

EID: 84861529382     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2012.01.017     Document Type: Article

References (54)

1. C. Baigent, L. Blackwell, R. Collins Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 2009 1849 1860
2. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
3. A.D. Calvin, N.R. Aggarwal, M.H. Murad Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes Diabetes Care 32 2009 2300 2306
4. J. Burn, A.M. Gerdes, F. Macrae Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial Lancet 378 2011 2081 2087
5. P. Rothwell, F.G. Fowkes, J.F. Belch, H. Ogawa, C.P. Warlow, T.W. Meade Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials Lancet 377 2011 31 41
6. J. Cuzick, F. Otto, J.A. Baron Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement Lancet Oncol 10 2009 501 507
7. P.C. Elwood, A.M. Gallagher, G.G. Duthie, L.A.J. Mur, G. Morgan Aspirin, salicylates, and cancer Lancet 373 2009 1301 1309
8. C. Bosetti, S. Gallus, C. La Vecchia Aspirin and cancer risk: a summary review to 2007 Recent Results Cancer Res 181 2009 231 251
9. E. Flossmann, P.M. Rothwell British Doctors Aspirin Trial and the UK-TIA Aspirin Trial Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies Lancet 369 2007 1603 1613
10. P.M. Rothwell, M. Wilson, C.-E. Elwin Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials Lancet 376 2010 1741 1750
11. B.F. Cole, R.F. Logan, S. Halabi Aspirin for chemoprevention of colorectal adenomas: meta-analysis of the randomised trials J Natl Cancer Inst 101 2009 256 266
12. D.L. Bhatt, J. Scheiman, N.S. Abraham ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents J Am Coll Cardiol 52 2008 1502 1517
13. J.S. Berger, M.J. Krantz, J.M. Kittelson, W.R. Hiatt Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials JAMA 301 2009 1909 1919
14. T. Wolff, T. Miller, S. Ko Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force Ann Intern Med 150 2009 405 410
15. T.J. Steiner, M. Voelker Gastrointestinal tolerability of aspirin and the choice of over-the-counter analgesia for short-lasting acute pain J Clin Pharm Ther 34 2009 177 186
16. V.L. Serebruany, A.I. Malinin, J.J. Ferguson, J. Vahabi, D. Atar, C.H. Hennekens Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients Fundam Clin Pharmacol 22 2008 315 321
17. P.J. Devereaux, M. Bhandary, V.M. Montori An observational study found that authors of randomized controlled trials frequently use concealment of randomization and blinding, despite the failure to report these methods J Clin Epidemiol 57 2004 1232 1236
18. M.O. Meade, G.H. Guyatt, R.J. Cook Agreement between alternative classifications of acute respiratory distress syndrome Am J Respir Crit Care Med 163 2001 490 493
19. F.A. McAlister, S.E. Straus, G.H. Guyatt, R.B. Haynes Users' guides to the medical literature: XX. Integrating research evidence with the care of the individual patient. Evidence-Based Medicine Working Group JAMA 283 2000 2829 2836
20. J.L. Fleiss The statistical basis of meta-analysis Stat Methods Med Res 2 1993 121 145
21. R. DerSimonian Laird N Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
22. J.P. Higgins, S.G. Thompson Quantifying heterogeneity in a meta-analysis Stat Med 21 2002 1539 1558
23. K. Thorlund, P.J. Devereaux, J. Wetterslev Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? Int J Epidemiol 38 2009 276 286
24. P. Laffort, R. Roudaut, X. Roques Early and long-term (one-year) effects of the association of aspirin and oral anticoagulant on thrombi and morbidity after replacement of the mitral valve with the St. Jude Medical prosthesis: a clinical and transesophageal echocardiographic study J Am Coll Cardiol 35 2000 739 746
25. R. Cote, R.N. Battista, M. Abrahamowicz, Y. Langlois, F. Bourque, A. Mackey Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing The Asymptomatic Cervical Bruit Study Group Ann Intern Med 123 1995 649 655
26. United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: interim results UK-TIA Study Group Br Med J (Clin Res Ed) 296 1988 316 320
27. E. Richard, R. Kuiper, M.G. Dijkgraaf, W.A. Van Gool Vascular care in patients with Alzheimer's disease with cerebrovascular lesions - a randomized clinical trial J Am Geriatr Soc 57 2009 797 805
28. H. Ogawa, M. Nakayama, T. Morimoto Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial JAMA 300 2008 2134 2141
29. G. Giannarini, A. Mogorovich, F. Valent Continuing or discontinuing low-dose aspirin before transrectal prostate biopsy: results of a prospective randomized trial Urology 70 2007 501 505
30. Final report on the aspirin component of the ongoing Physicians' Health Study Steering Committee of the Physicians' Health Study Research Group N Engl J Med 321 1989 129 135
31. R. Landolfi, R. Marchioli, J. Kutti Efficacy and safety of low-dose aspirin in polycythemia vera N Engl J Med 350 2004 114 124
32. Thrombosis Prevention Trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk The Medical Research Council's General Practice Research Framework Lancet 351 1998 233 241
33. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial Lancet 348 1996 633 638
34. M. Catalano, G. Born, R. Peto Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial J Intern Med 261 2007 276 284
35. L. Hansson, A. Zanchetti, S.G. Carruthers Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial HOT Study Group Lancet 351 1998 1755 1762
36. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial Lancet 355 2000 1295 1302
37. A.G. Turpie, M. Gent, A. Laupacis A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement N Engl J Med 329 1993 524 529
38. P. Lechat, H. Lardoux, A. Mallet Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontane; FFAACS) Cerebrovasc Dis 12 2001 245 252
39. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events The SALT Collaborative Group Lancet 338 1991 1345 1349
40. H.D. Lewis Jr, J.W. Davis, D.G. Archibald Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina Results of a Veterans Administration Cooperative Study N Engl J Med 309 1983 396 403
41. P. Casais, S.S. Meschengieser, A.G. Sanchez Luceros, E.I. Bermejo, M.A. Lazzari Effect of low-dose aspirin on the international normalized ratio variability in patients with mechanical heart valve prostheses Pathophysiol Haemost Thromb 32 2002 155 157
42. G. de Gaetano Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice Collaborative Group of the Primary Prevention Project Lancet 357 2001 89 95
43. J. Belch, A. MacCuish, I. Campbell The Prevention Of Progression of Arterial Disease And Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease BMJ 337 2008 a1840
44. P. Petersen, G. Boysen, J. Godtfredsen, E.D. Andersen, B. Andersen Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation The Copenhagen AFASAK study Lancet 1 1989 175 179
45. S. Juul-Moller, N. Edvardsson, B. Jahnmatz, A. Rosen, S. Sorensen, R. Omblus Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group Lancet 340 1992 1421 1425
46. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke EAFT (European Atrial Fibrillation Trial) Study Group Lancet 342 1993 1255 1262
47. A. Lanas, P. Wu, J. Medin, E.J. Mills Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis Clin Gastroenterol Hepatol 9 2011 762 768 e6
48. J. Ruschoff, S. Wallinger, W. Dietmaier Aspirin suppresses mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection Proc Natl Acad Sci U S A 95 1998 11301 11306
49. M.A. McIlhatton, J. Tyler, S. Burkholder Nitric oxide-donating aspirin derivatives suppress microsatellite instability in mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells Cancer Res 67 2007 10966 10975
50. S. Hernandez-Diaz, L.A. Garcia Rodriguez Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications BMC Med 4 2006 22
51. D.L. Bhatt, B.L. Cryer, C.F. Contant Clopidogrel with or without omeprazole in coronary artery disease N Engl J Med 363 2010 1909 1917
52. G.I. Leontiadis, C.W. Howden The role of proton pump inhibitors in the management of upper gastrointestinal bleeding Gastroenterol Clin North Am 38 2009 199 213
53. S. Yusuf, P. Pais, R. Afzal Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial Lancet 373 2009 1341 1351
54. S. Yusuf Two decades of progress in preventing vascular disease Lancet 360 2002 2 3